Andrew Powaleny Andrew Powaleny is Director of Public Affairs at PhRMA. Before joining PhRMA in 2015, he worked at the House Energy and Commerce Committee and later as a communications consultant. Andrew came to Washington, D.C. via Connecticut and proudly runs with the DC Front Runners and serves as its co-race director. He is also a member of the National Lesbian Gay Journalists Association and a proud alum of The Fund for American Studies. He’s passionate about scientific innovation, especially for mental illness, and his heroes are the men and women of America’s biopharmaceutical research companies.
Recent Posts
What scientific experts are saying about vaccine safety
By Andrew Powaleny | June 4, 2020
Vaccines have played a critical role in reducing the spread of, and in some cases, eliminating the threat of many devastating infectious diseases. They are often cited as second only to clean...
Read More
New report shows nearly 260 vaccines in development, including dozens for COVID-19
By Andrew Powaleny | April 23, 2020
Vaccines represent some of the most impactful advances in public health, helping to prevent the spread of many infectious diseases and, in many parts of the world, eliminating some of the most...
Read More
Merck’s Dr. Julie Gerberding on the threat of antimicrobial resistance and COVID-19
By Andrew Powaleny | April 6, 2020
As America’s biopharmaceutical companies work around the clock to combat COVID-19, a disease caused by a novel strain of coronavirus, now is an important time to consider how we can prepare for...
Read More
ICYMI: America’s biopharmaceutical companies are taking on COVID-19
By Andrew Powaleny | March 16, 2020
The biopharmaceutical industry is taking on COVID-19, a disease caused by a novel strain of coronavirus, through research and development (R&D) into prevention and treatment, in-kind financial...
Read More
Nearly 400 cell and gene therapies in development to target a broad range of diseases
By Andrew Powaleny | March 10, 2020
In 2017, the U.S. approved its first cell and gene therapy, making the idea of altering a gene to cure or treat a disease a reality. As the increasing pace of R&D propels cell and gene therapy...
Read More
ICYMI: Continued biopharmaceutical action on COVID-19
By Andrew Powaleny | March 6, 2020
Updated 3/11/2020 This week, PhRMA and senior executives and researchers from four member companies met with key policy makers on Capitol Hill to discuss the industry’s response to COVID-19, a...
Read More
R&D Focus: New report shows nearly 600 medicines in development for pediatric patients
By Andrew Powaleny | February 13, 2020
America’s biopharmaceutical researchers are committed to studying, developing and testing medicines to meet the unique needs of pediatric patients. New treatment options for infants, children and...
Read More
ICYMI: 2019 brings innovative medicines to patients
By Andrew Powaleny | January 17, 2020
New reports from the U.S. Food and Drug Administration (FDA) show a total of 55 novel new medicines were approved in 2019. Among these, 48 were approved by the Center for Drug Evaluation and...
Read More
ICYMI: Cancer death rate declines at record levels thanks to innovative medicines
By Andrew Powaleny | January 9, 2020
Each year, the American Cancer Society estimates the number of new cancer cases and deaths that will occur in the United States. For nearly 30 years, the trend towards fewer cancer deaths has been...
Read More
R&D Focus: Four ways the biopharmaceutical industry leads in delivering new treatments and cures
By Andrew Powaleny | December 9, 2019
In recent years, rapid advances in scientific discovery have ushered in a new era of medicine, transforming our ability to treat, and in some cases cure, some of the most challenging diseases,...
Read More
Medicare Monday (100)
340B Spotlight (43)
Cost & Consequence (0)
